Emverm (Mebendazole) Patent Expiration, LOE Window & CMS Spending

Emverm (Mebendazole) by Amneal Pharmaceuticals: Off-Patent Genericized (AB Competition), 0 AB generics, $26.6M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmneal Pharmaceuticals
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$26.6M
2024 Medicare Part D Spend$5.8M
2024 Medicaid Spend$20.8M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 32.7% 2-yr change)